BCIQ Profiles

Company Profile Report

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy
Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25 million from a private placement by

Read the full 402 word article

How to gain access

Continue reading with a
two-week free trial.